FDA heavily criticized by independent institute over Biogen approval

Independent US research institute ICER has criticized the FDA over its recent approval, saying it believes more studies are required to alleviate "substantial" uncertainty surrounding Biogen's drug, Aduhelm.

The US Food and Drug Administration (FDA) approved Biogen's Alzheimer's drug Aduhelm on Monday, and that decision is now being criticized.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading